U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07469657) titled 'Health Economic Evaluation of Non-Invasive Prenatal Exclusion Diagnosis' on Jan. 27.
Brief Summary: Since the discovery of a small fraction of circulating cell-free fetal DNA (ccffDNA) in the blood of the mother, non-invasive prenatal diagnosis (NIPD) techniques using a simple blood sample have been developed to 1) screen for chromosomal abnormalities, 2) diagnose fetal sex, and 3) detect variants not carried by the mother (exclusion NIPD by PCR).
Exclusion NIPD by PCR is currently available for certain common variants, but developing it for each variant takes 3-6 weeks per center. The development process for PCR NIPD is lengthy a...